四川和谐双马股份有限公司 2024年度独立董事述职报告 （述职人：周立） 一、独立董事的基本情况 周立，男，中国国籍，会计学教授，2001 年清华大学企业管理专业（会计 学方向）毕业，获博士学位。历任东南大学热能工程研究所讲师、副教授；清华 大学科技处副教授、副处长兼清华大学军工办公室主任；清华大学科技开发部主 任；清华大学企业集团董事；清华科技园发展中心董事；河北清华发展研究院院 长；清华大学副秘书长；北京市海淀区政府顾问；北京国家会计学院兼职教授； 昆明市呈贡县县委常委、副县长；昆明市政府市长助理；深圳市英威腾电气股份 有限公司、北京三元食品股份有限公司、江苏辉丰生物农业股份有限公司、上海 宽频科技股份有限公司等公司独立董事。现任清华大学经济管理学院会计系教授， 同时兼任长春英利汽车工业股份有限公司独立董事。不存在影响独立性的情况。 二、独立董事年度履职概况 （一）出席董事会及股东大会的情况 2023 年本人以通讯方式共出席五次董事会，均亲自出席会议，不存在委托 出席的情况。本人从企业管理及财会管理的专业角度，对相关议案进行详尽审查， 着重于所议事项的合规性、财务影响及风险控制，关注公司内部治理的持续完善 ...

Financial Performance - The company's revenue for Q1 2025 was ¥324,988,710.21, representing a 52.53% increase compared to ¥213,059,095.23 in the same period last year[5] - Net profit attributable to shareholders reached ¥116,549,153.25, a significant increase of 1,236.09% from ¥8,723,136.67 in the previous year[5] - The basic earnings per share rose to ¥0.15, marking a 1,400.00% increase from ¥0.01 in the same period last year[5] - Total operating revenue for the current period reached ¥324,988,710.21, a significant increase from ¥213,059,095.23 in the previous period, representing a growth of approximately 52.5%[23] - Net profit for the current period was ¥116,217,737.32, compared to ¥8,259,988.85 in the previous period, indicating a substantial increase of approximately 1,307.5%[24] - Total comprehensive income amounted to CNY 116,220,312.46, a significant increase from CNY 8,281,557.48 in the previous period[25] - Basic and diluted earnings per share both increased to CNY 0.15 from CNY 0.01[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥9,030,246,383.08, a 0.43% increase from ¥8,991,376,516.63 at the end of the previous year[5] - The company's total assets amounted to ¥9,030,246,383.08, up from ¥8,991,376,516.63, reflecting a growth of about 0.4%[22] - Total liabilities decreased to ¥1,360,958,888.76 from ¥1,438,309,334.74, showing a reduction of approximately 5.4%[22] - The company's total liabilities decreased by 58.19% in other payables, amounting to ¥38,241,994.79, primarily due to dividend payments to shareholders[10] - The company's equity attributable to shareholders increased to ¥7,591,869,474.09 from ¥7,475,317,745.70, representing a growth of about 1.6%[22] Cash Flow - The company reported a net cash flow from operating activities of ¥38,529,015.68, which is a decrease of 26.71% compared to ¥52,573,281.08 in the same period last year[5] - Cash inflow from operating activities reached CNY 352,461,745.55, compared to CNY 189,337,069.31 in the prior period, reflecting an increase of approximately 86.2%[25] - Net cash flow from operating activities was CNY 38,529,015.68, down from CNY 52,573,281.08, indicating a decrease of about 26.7%[25] - Cash outflow for investing activities totaled CNY 19,758,234.35, significantly lower than CNY 710,797,749.80 in the previous period[26] - Net cash flow from investing activities was CNY 1,074,123.67, a recovery from a negative cash flow of CNY -125,260,564.83 in the prior period[26] - The company reported a net increase in cash and cash equivalents of CNY 33,739,556.42, contrasting with a decrease of CNY -75,045,017.00 in the prior period[26] Shareholder Structure - The largest shareholder, Beijing Harmony Hengyuan Technology Co., Ltd., holds 26.52% of shares, totaling 202,446,032 shares, with 124,005,100 shares pledged[17] - The second largest shareholder, LAFARGE CHINA OFFSHORE HOLDING COMPANY (LCOHC) LTD., owns 17.55% of shares, amounting to 133,952,761 shares[17] - Tianjin Saike Environmental Management Center (Limited Partnership) holds 10.24% of shares, which is 78,203,902 shares[17] - CITIC Financial Asset Management Co., Ltd. possesses 7.45% of shares, equating to 56,854,045 shares[17] - Zhongrong Life Insurance Co., Ltd. holds 6.80% of shares, totaling 51,919,170 shares[17] - The Basic Pension Insurance Fund No. 1003 holds 1.23% of shares, which is 9,414,734 shares[17] - The top ten shareholders collectively represent a significant portion of the company's equity, with the largest three shareholders alone accounting for over 54%[17] - The shareholder structure indicates a concentration of ownership, which may impact governance and strategic decisions[17] Research and Development - Research and development expenses increased to ¥14,741,288.49, reflecting a 100.00% increase as a result of the acquisition of Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.[13] - Research and development expenses for the current period were ¥14,741,288.49, compared to ¥0.00 in the previous period, indicating a new investment in innovation[23] Fair Value and Investment Income - The company reported a significant increase in fair value gains of ¥82,252,243.83, compared to a loss of ¥66,419,972.85 in the previous year[13] - The company’s investment income showed a loss of ¥23,203,645.78, an improvement from a loss of ¥31,795,847.80 in the previous year[13] Future Outlook - Future outlook includes plans for market expansion and potential new product launches, aiming to sustain growth momentum[23] Other Information - The company did not undergo an audit for the first quarter report[27] - The company is set to implement new accounting standards starting from 2025[28]

Financial Performance - Total revenue for 2024 was CNY 107,455.77 million, a decrease of 11.87% compared to CNY 121,934.46 million in the previous year[3] - Operating profit fell to CNY 29,182.95 million, down 74.32% from CNY 113,621.30 million year-on-year[3] - Net profit attributable to shareholders decreased by 68.61% to CNY 30,938.14 million from CNY 98,547.36 million in the previous year[3] - The basic earnings per share dropped to CNY 0.41, a decline of 68.22% compared to CNY 1.29 in the previous year[3] - The net profit after deducting non-recurring gains and losses was CNY 6,052.96 million, a significant drop of 93.55% from CNY 93,871.11 million year-on-year[3] - The weighted average return on equity decreased to 4.17%, down 9.93 percentage points from 14.10% in the previous year[3] Operational Challenges - The company faced challenges due to capital market fluctuations and slow recovery in market demand for building materials, impacting overall sales volume and prices[5] - The company is actively optimizing operational efficiency and controlling costs to mitigate the impact of declining performance[5] Strategic Initiatives - A strategic acquisition of Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. was made to establish a solid foundation for future growth[5] Asset Management - Total assets increased by 9.72% to CNY 899,137.65 million from CNY 819,460.89 million at the beginning of the period[3]

Financial Performance - The company expects a net profit attributable to shareholders of 100 million to 140 million CNY, representing a growth of 1,047% to 1,506% compared to the same period last year, where the profit was 8.72 million CNY[3] - The net profit after deducting non-recurring gains and losses is projected to be 95 million to 135 million CNY, compared to a loss of 4.21 million CNY in the previous year[3] - Basic earnings per share are estimated to be between 0.13 CNY and 0.18 CNY, up from 0.01 CNY in the same period last year[3] - The significant increase in performance is primarily attributed to good returns from the funds invested by the company during the reporting period[5] Strategic Focus - The company is focusing on cost reduction and efficiency improvement while increasing investment in technological innovation and market expansion[6] - The company aims to lay a solid foundation for stable and healthy future development through its current strategies[6] Earnings Forecast - The earnings forecast is based on preliminary calculations and has not been audited by registered accountants[4] Share Capital - The total share capital as of March 31, 2025, is 763,440,333 shares, with 6,219,875 shares in the repurchase special securities account[3] Information Disclosure - The company emphasizes the importance of timely information disclosure and advises investors to make cautious decisions due to potential risks[7] - The detailed financial data will be disclosed in the first quarter report of 2025[7]

证券代码：000935 证券简称：四川双马 公告编号：2025-9 四川和谐双马股份有限公司 关于控股股东所持部分股份质押展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川和谐双马股份有限公司(简称"公司"）于近日接到控股股东北京和谐 恒源科技有限公司（简称"和谐恒源"）的告知函，获悉和谐恒源对所持有的本 公司的部分股份办理了质押展期业务，具体事项如下： 上述"占其所持股份比例"为该笔质押股份的数量占和谐恒源及其一致行动 人持股数量的比例。所质押的股份未负担重大资产重组等业绩补偿义务。 上述股份的原质押情况详见公司于2024年4月24日及2024年4月26日披露的 《关于控股股东所持部分股份解除质押及再质押的公告》和《关于控股股东所持 部分股份解除质押及再质押的公告》。依据和谐恒源出具的告知函，和谐恒源对 所持有的本公司的部分股份办理质押展期的主要原因为偿还债务，就质押事项和 谐恒源具备履约偿债能力，所质押的股份不存在平仓风险，对上市公司的生产经 营及公司治理等不会产生影响，和谐恒源已采取相关防范应对措施。 二、股东股份累计被质押的情况 股 东 ...

证券代码：000935 证券简称：四川双马 公告编号：2025-8 四川和谐双马股份有限公司 关于公司董事、副总经理兼董事会秘书辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川和谐双马股份有限公司（以下简称"公司"）董事会于 2025 年 3 月 31 日收到公司董事、副总经理兼董事会秘书陈长春先生提交的书面辞职报告，陈长 春先生由于个人原因提请辞去公司董事、副总经理兼董事会秘书的职务，辞职后 不再担任公司及控股子公司的其他职务。 陈长春先生的辞职不会导致公司董事会成员人数低于法定最低人数，不会影 响公司董事会的正常运作及公司经营管理的正常运行。根据《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》等相关规定，陈长春先 生的辞职报告自送达公司董事会之日起生效。截至本公告披露日，陈长春先生未 持有公司股份，不存在应当履行而未履行的承诺事项。 通讯地址：四川省成都市锦江区红星路三段一号成都国际金融中心 1 号写 字楼 26 楼 2 号 电子邮箱：public.sm@sc-shuangma.com 特此公告。 四川和谐双马股份 ...

Group 1 - The core viewpoint of the article is that Sichuan Shuangma (000935) has invested in a smart mobility fund that includes Xiaopeng Motors, and any increase in Xiaopeng's stock price will positively impact the company's performance [1] - The company acknowledges that the stock price changes of its invested listed companies will affect its financial reports, indicating a level of uncertainty [1]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 22.27 RMB based on a valuation of 170 billion RMB for 2025 [3]. Core Insights - The company is expected to benefit from a favorable technology growth style and an improving exit channel for its private equity business, leading to anticipated earnings elasticity [3]. - The report highlights significant investments in technology sectors, including participation in funds that have invested in leading companies in AI and robotics, which are expected to drive future growth [1][2]. Summary by Sections Investment Projects - The company has invested in Hangzhou Qunhe Information Technology Co., which has submitted a listing application to the Hong Kong Stock Exchange, and in the Fourier project in the robotics industry [1]. - Fourier has completed a new financing round totaling nearly 800 million RMB and provides robotic solutions widely used in medical rehabilitation and academic research [2]. Financial Forecasts - The projected net profits for the company are 3.5 billion RMB in 2024, 6.5 billion RMB in 2025, and 9.5 billion RMB in 2026, reflecting a year-on-year change of -64%, +85%, and +47% respectively [3]. - Revenue is expected to decline to 1.006 billion RMB in 2024 before rebounding to 1.456 billion RMB in 2025 and 1.775 billion RMB in 2026, with growth rates of -17.5%, +44.8%, and +21.9% respectively [6]. Market Performance - The report notes that several investment projects have successfully gone public, with significant stock price increases since 2025, including a 95.9% increase for Aojie Technology and a 60.2% increase for BGI Intelligent Manufacturing [2].

证券代码：000935 证券简称：四川双马 公告编号：2025-7 四川和谐双马股份有限公司 关于控股子公司湖北健翔 获得化学原料药上市申请批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 四川和谐双马股份有限公司（简称"公司"）控股子公司湖北健翔生物制药 有限公司（简称"湖北健翔"）于近期获得国家药品监督管理局核准签发的缩宫 素《化学原料药上市申请批准通知书》。现将相关情况公告如下： 一、本次获得化学原料药上市申请批准通知书的具体情况 1、化学原料药名称 （1）通用名称:缩宫素 （2）英文名/拉丁名:Oxytocin 2、登记号:Y20220001017 6、有效期：24 个月 7、包装规格：200g/听 8、申请事项：境内生产化学原料药上市申请。 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 10、生产企业： （1）名称：湖北健翔生物制药有限公司 （2）地址：湖北咸宁咸安经济开发区绿山路 9 号 3、受理号:CYHS2360428 4、通知书编号: ...

Group 1: Company Overview and Acquisition - Sichuan Harmony Shuangma Co., Ltd. is engaged in industrial investment and management, as well as private equity fund management, with a focus on building materials and private equity investment funds [2] - In 2024, the company completed the acquisition of Shenzhen Jianyuan, expanding its business scope and strategic deployment [2] Group 2: Production Capacity and Market Position - Shenzhen Jianyuan's annual production capacity exceeds 4 tons, with a maximum batch size of 100 kg; specifically, the GLP-1 raw material capacity is 2 tons, with a single batch size reaching 20 kg [3] - The global GLP-1 drug market has grown from $9.3 billion in 2018 to $38.9 billion in 2023, with a compound annual growth rate (CAGR) of 33.2%, projected to reach $98.8 billion by 2028 with a CAGR of 20.5% [5] Group 3: Revenue and Product Segmentation - In 2024, GLP-1 raw materials are expected to account for approximately 70% of Shenzhen Jianyuan's revenue, with major products contributing over 20% and 40% respectively [4] - The company has received orders for oral formulations of semaglutide, with significant sales expected this year [4] Group 4: Strategic Development and Future Plans - The company has plans for capacity expansion in response to market demand for GLP-1 products, with ongoing construction based on market changes [3] - Future growth is anticipated as Shenzhen Jianyuan enters a rapid development phase, leveraging its technological and market advantages [4] Group 5: Investment and Fund Management - As of June 30, 2024, the company generated investment income of 1.654 billion yuan from two funds, with an expected increase in excess performance remuneration as the capital market recovers [4] - The Harmony Green Industry Fund has begun project investments, focusing on high-end manufacturing, artificial intelligence, new energy, and semiconductors [4] Group 6: Corporate Governance and Management Enhancements - Post-acquisition, Sichuan Harmony Shuangma restructured Shenzhen Jianyuan's board and management, enhancing operational efficiency and risk control [5] - The company is committed to establishing a robust internal control system and optimizing management processes to ensure high operational efficiency [5]